Every 424B that Avalo Therapeutics, Inc. (AVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics, Inc. filed a resale prospectus covering up to 128,189 shares of common stock, $0.001 par value, held by former AlmataBio stockholders under a Milestone Buyout Amendment Agreement. All shares may be sold from time to time by the selling stockholders; Avalo is not selling shares and will not receive proceeds from these resales.
Avalo is a clinical-stage biotechnology company focused on therapies targeting the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases. Lead antibody abdakibart (AVTX-009) met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa and is planned for advancement into a registrational Phase 3 program. As of July 10, 2026, there were 52,902,989 shares of common stock outstanding; AVTX trades on Nasdaq Capital Market, last reported at $19.50 per share on July 27, 2026.
Avalo Therapeutics is offering 19,730,000 shares of common stock and pre-funded warrants to purchase up to 1,400,000 additional shares. The offering price is $17.75 per share and each pre-funded warrant has an exercise price of $0.001 per share. The company estimates net proceeds of approximately $352.1 million, which it intends to use to advance the clinical development of abdakibart (AVTX-009) into a Phase 3 registrational program, for working capital and general corporate purposes. Avalo reported $82.0 million of cash, cash equivalents and short-term investments as of March 31, 2026. The pre-funded warrants are non‑expiring, subject to ownership limits (4.99% default; holder may elect 9.99%), and are not expected to be listed.
Avalo Therapeutics is offering shares of its common stock and, in lieu of shares to certain investors, pre-funded warrants exercisable for common stock, subject to 4.99% (or, at holder election, 9.99%) ownership limits. The company reported positive Phase 2 topline results for abdakibart in HS and lists common stock on Nasdaq under AVTX. The prospectus describes underwriting arrangements, an underwriter option to purchase additional shares, intended use of proceeds to advance abdakibart into Phase 3, and a preliminary cash position of approximately $82.0 million as of March 31, 2026.